Blood group typing has always been one of those unglamorous but non-negotiable parts of healthcare — you can't transfuse blood, transplant an organ, or safely deliver a baby with a Rh-incompatible pregnancy without it. It doesn't make headlines the way a new cancer drug or a surgical robot does, and most people only think about it when they're filling out a donor card or waiting anxiously outside an operating room. But behind the scenes, every single unit of blood that moves from a donor's arm to a patient's vein has to pass through this exact process first — a quick, almost invisible checkpoint that determines whether a transfusion saves a life or endangers one.

That's what makes blood group typing market so interesting to watch. It isn't chasing a trend or riding a single breakthrough technology. It's foundational infrastructure — the kind of testing that has to happen regardless of economic cycles, regardless of which new therapies are in vogue, because hospitals, blood banks, and transplant centers simply cannot function without it. And yet, even a category this fundamental isn't standing still. Rising chronic disease rates, an aging global population, a growing volume of surgeries and organ transplants, and a steady shift from manual serology toward automated and molecular testing are all pushing this quiet corner of diagnostics into a genuine growth story. That quiet necessity is now translating into serious market momentum.

Market Overview and Key Metrics

The global blood group typing market was valued at USD 2.3 billion in 2025 and is projected to grow from USD 2.5 billion in 2026 to USD 5.6 billion by 2033, at a CAGR of 12.0% from 2026 to 2033. That's roughly a 2.3x increase in market size over the forecast window — a steep growth curve for what is fundamentally a diagnostics niche.

What's driving it? A few converging forces:

• Chronic disease burden. The rising burden of chronic diseases such as anemia, cancer, and blood disorders is increasing the need for frequent transfusions. The scale here is significant — anemia affects nearly 30% of women of reproductive age and around 40% of children under five globally.
• Trauma and transplant volumes. A growing number of surgical procedures, organ transplants, and trauma cases is driving demand for accurate blood compatibility testing, with over 173,000 solid organ transplants performed worldwide in 2024 alone.
• Rising donation volumes needing screening. Over 118.5 million blood donations are collected globally each year, and every single one requires mandatory blood grouping and screening before use.

On the product side, reagents & consumables dominate the market, accounting for a 72.2% revenue share in 2025, driven by the recurring nature of reagent and consumable purchasing across blood banks and labs. Meanwhile, antibody screening leads the test-type segment with a 38.9% share in 2025, given its central role in flagging unexpected antibodies before transfusions and surgeries.

Download a Free Sample Report — see the full data behind these numbers.

Regional Share

Geography tells its own story here:

• North America leads decisively, accounting for a 44.2% revenue share in 2025, underpinned by advanced healthcare infrastructure, high adoption of automated and molecular diagnostics, and strong regulatory frameworks. Within the region, the U.S. holds the largest share, supported by high transfusion and transplant volumes and early adoption of molecular typing technology.
• Asia Pacific is the one to watch, projected to post the fastest growth of any region through 2033. Growth here is fueled by expanding healthcare infrastructure in countries like India and China, government-backed blood bank modernization, and a much larger patient pool gaining better access to diagnostic services.
• Europe remains a mature, tightly regulated market anchored by strong national blood services and transfusion safety standards.
• Latin America and the Middle East & Africa are growing more gradually, constrained in places by limited access to advanced technologies, but benefiting from ongoing global initiatives to improve blood safety infrastructure.

The Bottom Line

Blood group typing sits at an interesting inflection point: it's a mature, essential diagnostic category being reshaped by a shift toward molecular and automated testing (PCR, microarray, NGS-based genotyping), while demand keeps climbing on the back of an aging, sicker global population and rising surgical and transplant volumes. For companies in reagents, instruments, or molecular diagnostics, this is a market where the fundamentals and the innovation curve are both pointing the same direction.

Want the full picture — segment-level forecasts, competitive benchmarking, and country-level data? Speak to an Analyst — get a direct, free answer to your specific questions within 1 working day.